What the labels report
| Wegovy 2.4 mg | Placebo | Zepbound 5 / 10 / 15 mg | Placebo | |
|---|---|---|---|---|
| Indigestion (dyspepsia) | 9% | 3% | 9 / 9 / 10% | 4% |
| Reflux (GERD) | 5% | 3% | 4 / 4 / 5% | 2% |
| Gastritis | 4% | 1% | not tabled |
Why it may happen
Food staying longer in a slowed stomach is the usual explanation: a fuller stomach for longer gives more opportunity for acid to move up into the food pipe.[3] It is reasonable, but no trial has tested it directly in GLP-1 users. Large late meals and lying down soon after eating are general reflux triggers that apply here as anywhere.
When chest symptoms are urgent
- Chest pain or pressure, especially with breathlessness, sweating, or pain in the arm or jaw: emergency care; do not assume it is heartburn
- Trouble swallowing or food sticking
- Vomiting blood or black stools
The short version
Short on the way. A 35-second captioned version of this page is in production for the Fewer Bites channel. It will be embedded here when it is live.
Questions to bring to your prescriber
Print these or screenshot them. They are conversation starters, not a checklist of things to do.
- Which heartburn medicines are safe with my other prescriptions?
- Are my symptoms reflux, or should we check for something else?
Education, not advice. This page explains what trials, labels and guidelines report. It does not tell anyone to start, change or stop a medicine. Your prescriber knows your history; this page does not.
Sources
- Novo Nordisk / FDA. Wegovy (semaglutide) injection and tablets, prescribing information, revised 06/2026. label
- Eli Lilly / FDA. Zepbound (tirzepatide) prescribing information, revised 08/2026. label
- Hiramoto B et al. Quantified metrics of gastric emptying delay by GLP-1 receptor agonists: systematic review and meta-analysis. Am J Gastroenterol 2024;119:1126–40. primary read · meta-analysis